<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Exogenous delivery of vascular endothelial growth factor gene (VEGF) may provide a useful approach to the treatment of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the use of a <z:mp ids='MP_0005039'>hypoxia</z:mp>-responsive element to control VEGF expression given for neuroprotection </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Three groups (n=36) of mice received AAVH9-VEGF, AAVH9-lacZ, or saline injection </plain></SENT>
<SENT sid="3" pm="."><plain>Five days after gene transfer, the mice underwent 45 minutes of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) followed by 1 to 7 days of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was determined using <z:chebi fb="0" ids="52815">cresyl violet</z:chebi> staining; neuronal injury was examined using TUNEL, cleaved caspase-3, and fluoro-Jade B staining </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:mp ids='MP_0005039'>Hypoxia</z:mp>-inducible factor-1 (HIF-1) was overexpressed after tMCAO in the ischemic hemisphere in the brain </plain></SENT>
<SENT sid="6" pm="."><plain>Expression of lacZ, mediated by AAV-lacZ, was seen before and after tMCAO; however, AAVH9-lacZ-mediated lacZ expression was detected only after tMCAO </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was smaller in the AAVH9-VEGF-transduced group compared with AAVH9-lacZ and saline groups (55% reduction, P&lt;0.05) with reduced TUNEL (29+/-5% and 30+/-7% versus 12+/-3%, P&lt;0.05), cleaved caspase-3 (20+/-3% and 21+/-5% versus 13+/-4%, P&lt;0.05) and fluoro-Jade B (23+/-3% and 24+/-5% versus 12+/-5%, P&lt;0.05) -positive neurons, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Exogenous expression of VEGF through AAVH9-VEGF gene transfer 5 days before the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> provides neuroprotection </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0005039'>Hypoxia</z:mp>-responsive element is a viable strategy of restricting VEGF expression to areas of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> to minimize adverse effects of therapy on adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> parenchyma </plain></SENT>
</text></document>